Teclistamab for Waldenström's macroglobulinemia that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a drug called teclistamab for people with Waldenström's macroglobulinemia that has come back or not responded to other treatments. Teclistamab is a type of immunotherapy that helps your immune system find and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Waldenström's macroglobulinemia (a rare blood cancer).
- You must have had at least one prior treatment, including an anti-CD20 antibody (like rituximab) or a BTK inhibitor (like ibrutinib).
- You should not have had a previous treatment that targets BCMA (a protein on myeloma cells).
- You must be 18 or older and generally able to care for yourself (ECOG score 0–2).
- You need adequate blood counts and organ function (kidney, liver) as determined by tests.
- You must agree to use contraception (if applicable) and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
Hear when a new Waldenstrom's Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.